Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Report: Information by Disease Outlook, Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Others), End User (Pharmaceutical Companies and CROs, Others) and Region - Forecast till 2027
ID: MRFR/HC/6512-CR | June 2019 | Region: Global | 111 pages
Market Overview
TheGlobal Non-Alcoholic Steatohepatitis Biomarkers Market is Expected to Register a CAGR of 20.92% and is Anticipated to Reach USD 1,960.4 million by 2024. Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD), which is characterized by liver inflammation and damage caused by a buildup of fat in the liver. Currently, there is no single test approved for diagnosing non-alcoholic steatohepatitis.
The market of non-alcoholic steatohepatitis biomarkers is expected to grow very well in the forecast period with around 30.3% CAGR. The market was valued to be USD 200.4 million in 2016, which is expected to reach more than 2100.6 million by 2027. The rapid growth of this market is expected to happen due to the rising NASH prevalence, raising awareness all around the world, and demand for non-invasive tests. Non-alcoholic steatohepatitis biomarkers is a disease type that is marked by liver inflammation.
The government funds are increasing for the non-alcoholic steatohepatitis biomarkers research, innovations, technology advancement, and others. It can affect the market significantly to increase the growth. Apart from governments, there are many non-profit organizations around the world that are supporting the non-alcoholic steatohepatitis biomarkers market by spreading awareness and making investments. There are many initiatives that are under the process that can create growth opportunities for this market in the forecast period.
Covid 19 Analysis
COVID 19 affected the global economy by temporarily shutting down many industries. Among all of them, the non-alcoholic steatohepatitis biomarkers market also suffered a lot during the time of the pandemic. The production chain, manufacturing, everything got disrupted during the lockdown. Although most of the regions have resumed successfully, there are some places where the companies are still preparing. The demand for diagnostic tools that are non-invasive has increased a lot during the period. So, the economic condition of the market is expected to grow very fast.
Market Dynamics
- Drivers
The major driving factors of the non-alcoholic steatohepatitis biomarkers market are the increasing demand for diagnostic tools that are not invasive and the rising awareness of patients. The cost of liver biopsy is very high, not very much accepted by the patients, and invasiveness makes the invasive techniques less adopted by the patients and healthcare professionals. Due to all these disadvantages of invasive techniques, the non-alcoholic steatohepatitis biomarkers market is projected to grow a lot.
While some of the techniques like magnetic resonance imaging, computed tomography, and ultrasound scanning can help to get accurate NAFLD results. They fail to detect liver fibrosis in most instances. So, the demand for noninvasive diagnostic tools gets even higher with the only accurate detection. In the upcoming years, the non-alcoholic steatohepatitis biomarkers market is expected to grow very well due to these factors.
- Opportunities
The increasing number of initiatives in the non-alcoholic steatohepatitis biomarkers market is expected to develop the growth of this market. For example, the NASH Education Program is one of the very good initiatives that is started by the company named GENFIT in the year 2016 that helps to spread awareness to people about NASH. These types of initiatives are expected to open many opportunities for the non-alcoholic steatohepatitis biomarkers market.
- Restraints
Although the non-alcoholic steatohepatitis biomarkers market is expected to witness high growth in the forecast period, there are some factors that can slow it down. One of the major factors among them is the restriction of the US FDA for the biomarkers is expected to create hurdles for the market growth. Apart from that, the high cost of the tools is also hindering the growth of this market.
- Challenges
Some of the common challenges that the non-alcoholic steatohepatitis biomarkers market need to overcome are the government policies. Also, the strict regulations of the US FDA make it hard for the non-alcoholic steatohepatitis biomarkers market to grow very much. However, the latest research and innovations in the upcoming years are expected to overcome all the challenges. After the COVID 19, most of the companies have come out of the bad situation and resumed their manufacturing to provide the high demand.
- Cumulative Growth Analysis
The growth in the market of non-alcoholic steatohepatitis biomarkers is expected to rise more than USD 200.4 million in the forecast period. With a high CAGR of 30.3%, the market is expected to have high growth during the forecast period. With the rising demand for non-surgical procedures, absence of NASH treatment test, spreading awareness of government and nonprofit organizations is expected to propel the growth of the non-alcoholic steatohepatitis biomarkers market in the forecast period.
Value Chain Analysis
As NASH is an increasing disease in almost all regions, very high funding and investments are contributed by different organizations and governments for advancement. Companies around the world are now keeping their ears and eyes open to have an effective cure. While strict regulations and others are holding back the growth of the non-alcoholic steatohepatitis biomarkers market, it is expected that the market will grow with the spreading awareness and demand of the biomarkers among patients and healthcare professionals.
Segment Overview
The global market of non-alcoholic steatohepatitis biomarkers is segmented into end-user and type. Here are the sub-segments of these segments are given below.
By Type,
- Hepatic Fibrosis Biomarkers
- Serum Biomarkers
- Oxidative Stress Biomarkers
- Apoptosis Biomarkers
- Others
Among all of these sub-segments, the serum biomarkers hold the largest non-alcoholic steatohepatitis biomarkers market share by type. It is mostly due to the associated benefits like efficient outcomes, distinguishing ability from simple steatosis and NASH, and others. It is the most common tool of diagnosis that is used to detect NASH. Some of the other product introductions like tumor & ghrelin necrosis factor-alpha, leptin, apolipoprotein B, free fatty acids, adiponectin, apolipoprotein A1, and others are provided better services than the traditional ones.
By End-User,
- Research Institutes and Academics
- Diagnostic Centres
- Pharmaceutical Companies and CROs
- Hospitals and Clinics
- Others
The largest share of the non-alcoholic steatohepatitis biomarkers market is occupied by the pharmaceutical industry. The growth of this segment is expected to rise more because of the demand for monitoring tools, non-invasive NASH diagnostic, and others.
Regional Analysis
There are mainly 5 regions that are known for having very good non-alcoholic steatohepatitis biomarkers market growth such as Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. Among them, Asia Pacific is expected to have the best growth during the forecast period based on the R & D rise in Japan and China, increased awareness, new technologies, and others.
Competitive Landscape
There are many companies available in the market that are leading the non-alcoholic steatohepatitis biomarkers market. Also, many new players are entering the market with improved strategies and innovations. Some of the major players in this market areOne Way Liver, BioPredictive, Cisbio, Celerion, Enterome, Echosens, GENFIT, NGM Biopharmaceuticals, and many others.
List of Key Companies:
- Perspectum Diagnostics Ltd.
- Shenzhen New Industries Biomedical Engineering Co Ltd
- One Way Liver SL
- BioPredictive
- Cisbio
- Celerion
- Enterome
- Echosens
- GENFIT
- NGM Biopharmaceuticals
- Laboratory Corporation of America Holdings
- Pacific Biomarkers
- Quest Diagnostics Ltd
- Prometheus Laboratories Inc
- Regulus Therapeutics Inc.
- Xeptagen SpA
- Boehringer Ingelheim GmbH Inc.
- Bristol-Myers Squibb
- AstraZeneca
- Pfizer Inc.
Recent Developments
- Quest Diagnostics made a partnership with Houston Healthcare to improve the delivery services of the laboratory in 2018. They are expected to boost their position with this partnership in the upcoming years
- Siemens Healthineers in 2018 November, announced the approval of the RLF test breakthrough from the FDA. It is intended to help the patients get more effective and time-efficient diagnoses to get better treatment from the life-threatening disease.
- Prometheus launched the FIBROSpect NASH test in 2017 October to help the NASH patients get better services based on liver fibrosis severity. The company is expecting to catch up to a higher position in the market with the introduction of this test.
Report Overview
This report contains in-depth information about both the market growth of nonalcoholic steatohepatitis biomarkers and regional growth analysis. Apart from that, there are some sections like challenges, restraints, drivers, growth analysis, segmentation, competitive landscape, and many more. All the information that is provided in this report is taken from different primary and secondary sources to provide the best growth projection in the forecast period.
Report Detail
- Historic Period: 2018-2021
- Base Year: 2021
- Forecast Period: 2021-2027
By Geographically:
- Asia Pacific
- Europe
- North America
- Latin America
- Middle East & Africa
Frequently Asked Questions (FAQ) :
Among all the different segments, Serum biomarkers hold the largest market share of non-alcoholic steatohepatitis biomarkers with more than 32.3% due to major benefits like understanding NASH from simple steatosis that makes the outcomes efficient. With these benefits, the need of doing liver biopsy has reduced and increased the growth of this market.
Major key players of the non-alcoholic steatohepatitis biomarkers market are AstraZeneca, GENFIT, Bristol-Myers Squibb, Boehringer Ingelheim GmbH Inc., Gilead, Novartis, Pfizer Inc., Quest Diagnostics, Siemens Healthineers, Xeptagen SPA, Prometheus Laboratories Inc, Laboratory Corporation of America Holdings, One way Liver SL, NGM Biopharmaceuticals, Echosens, BioPredictive, Cisbio, Celerion, Enterome, Shenzhen New Industries Biomedical Engineering Co. Ltd., and others. Many new companies are entering the non-alcoholic steatohepatitis biomarkers market with new strategies and products.
The global non-alcoholic steatohepatitis biomarkers market is expected to grow more than 2.20 billion in the forecast period. The CAGR is projected to be around 30.4% with the increasing chronic liver condition cases.
1 Executive Summary
1.1 Market Attractiveness Analysis 16
2 Market Introduction
2.1 Definition 18
2.2 Scope Of The Study 18
2.3 Assumptions 18
2.4 Market Structure 18
3 Research Methodology
3.1 Research Process 19
3.2 Primary Research 20
3.3 Secondary Research 21
3.4 Market Size Estimation 22
3.5 Forecast Model 22
4 Market Dynamics
4.1 Overview 23
4.2 Drivers 24
4.2.1 Increasing Prevalence Of Diabetes And Obesity 24
4.2.2 Growing Demand For Non-Invasive Tests 24
4.2.3 Rising Public And Private Sector Initiatives To Increase Awareness About NASH 24
4.3 Restraints 25
4.3.1 Stringent Regulatory Scenario 25
4.4 Opportunities 25
4.4.1 Growing Mergers And Acquisitions To Develop Novel Biomarkers 25
5 Market Factor Analysis
5.1 Value Chain Analysis 26
5.1.1 R&D And Designing 26
5.1.2 Manufacturing 26
5.1.3 Distribution & Sales 26
5.1.4 Post-Sales Review 27
5.2 Porter’s Five Forces Model 27
5.2.1 Bargaining Power Of Suppliers 27
5.2.2 Bargaining Power Of Buyers 28
5.2.3 Threat Of New Entrants 28
5.2.4 Threat Of Substitutes 28
5.2.5 Intensity Of Rivalry 28
5.3 Pipeline Analysis 28
5.3.1 Overview 28
5.3.2 Recent Developments In Product Pipeline 29
5.4 Regulatory Landscape 29
5.5 Non-Alcoholic Steatohepatitis Biomarkers: Disease Cause Outlook 30
5.5.1 Overview 30
5.5.2 Obesity 30
5.5.3 Type 2 Diabetes 30
5.5.4 Hyperlipidemia 31
5.5.5 Hypertension 31
5.5.6 Metabolic Syndrome (MetS) 31
6 Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
6.1 Overview 32
6.2 Serum Biomarkers 34
6.3 Hepatic Fibrosis Biomarkers 35
6.4 Apoptosis Biomarkers 37
6.5 Oxidative Stress Biomarkers 38
6.6 Others 38
7 Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
7.1 Overview 39
7.2 Pharmaceutical Companies And CROs 41
7.3 Research Institutes And Academic Centers 42
7.4 Diagnostic Centers 43
7.5 Hospitals & Clinics 44
8 Global Non-Alcoholic Steatohepatitis Biomarkers Market, By Region
8.1 Overview 45
8.2 Americas 47
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.2.1 North America 49
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.2.1.1 US 51
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.2.1.2 Canada 52
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.2.2 Latin America 53
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3 Europe 55
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3.1 Western Europe 58
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3.1.1 UK 60
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3.1.2 Germany 61
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3.1.3 France 62
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3.1.4 Italy 63
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3.1.5 Spain 64
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3.1.6 Rest Of Western Europe 65
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.3.2 Eastern Europe 66
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.4 Asia-Pacific 67
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.4.1 Japan 69
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.4.2 China 70
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.4.3 India 71
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.4.4 Australia 72
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.4.5 South Korea 73
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.4.6 Rest Of Asia-Pacific 74
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.5 Middle East & Africa 76
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.5.1 Middle East 78
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
8.5.2 Africa 79
Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
Non-Alcoholic Steatohepatitis Biomarkers Market, By End User
9 Competitive Landscape
9.1 Overview 81
9.2 Key Development Analysis 82
10 Company Profiles
10.1 BioPredictive 83
10.1.1 Company Overview 83
10.1.2 Financial Overview 83
10.1.3 Products/Services Offered 83
10.1.4 Key Developments 83
10.1.5 SWOT Analysis 83
10.1.6 Key Strategies 84
10.2 Celerion 85
10.2.1 Company Overview 85
10.2.2 Financial Overview 85
10.2.3 Products/Services Offered 85
10.2.4 Key Developments 85
10.2.5 SWOT Analysis 85
10.2.6 Key Strategies 85
10.3 Cisbio 86
10.3.1 Company Overview 86
10.3.2 Financial Overview 86
10.3.3 Products/Services Offered 87
10.3.4 Key Developments 87
10.3.5 SWOT Analysis 88
10.3.6 Key Strategies 88
10.4 Echosens 89
10.4.1 Company Overview 89
10.4.2 Financial Overview 89
10.4.3 Products/Services Offered 89
10.4.4 Key Developments 89
10.4.5 SWOT Analysis 90
10.4.6 Key Strategies 90
10.5 Enterome 91
10.5.1 Company Overview 91
10.5.2 Financial Overview 91
10.5.3 Products/Services Offered 91
10.5.4 Key Developments 91
10.5.5 SWOT Analysis 91
10.5.6 Key Strategies 91
10.6 GENFIT 92
10.6.1 Company Overview 92
10.6.2 Financial Overview 92
10.6.3 Products/Services Offered 92
10.6.4 Key Developments 92
10.6.5 SWOT Analysis 93
10.6.6 Key Strategies 93
10.7 Laboratory Corporation Of America Holdings 94
10.7.1 Company Overview 94
10.7.2 Financial Overview 94
10.7.3 Products/Services Offered 95
10.7.4 Key Developments 95
10.7.5 SWOT Analysis 95
10.7.6 Key Strategies 95
10.8 NGM Biopharmaceuticals 96
10.8.1 Company Overview 96
10.8.2 Financial Overview 96
10.8.3 Products/Services Offered 96
10.8.4 Key Developments 96
10.8.5 SWOT Analysis 96
10.8.6 Key Strategies 96
10.9 One Way Liver, SL 97
10.9.1 Company Overview 97
10.9.2 Financial Overview 97
10.9.3 Products/Services Offered 97
10.9.4 Key Developments 97
10.9.5 SWOT Analysis 97
10.9.6 Key Strategies 97
10.10 Pacific Biomarkers 98
10.10.1 Company Overview 98
10.10.2 Financial Overview 98
10.10.3 Products/Services Offered 98
10.10.4 Key Developments 98
10.10.5 SWOT Analysis 99
10.10.6 Key Strategies 99
10.11 Prometheus Laboratories Inc. 100
10.11.1 Company Overview 100
10.11.2 Financial Overview 100
10.11.3 Products/Services Offered 101
10.11.4 Key Developments 101
10.11.5 SWOT Analysis 101
10.11.6 Key Strategies 101
10.12 Perspectrum Diagnostics Ltd 102
10.12.1 Company Overview 102
10.12.2 Financial Overview 102
10.12.3 Products/Services Offered 102
10.12.4 Key Developments 102
10.12.5 SWOT Analysis 102
10.12.6 Key Strategies 102
10.13 Quest Diagnostics 103
10.13.1 Company Overview 103
10.13.2 Financial Overview 103
10.13.3 Products/Services Offered 104
10.13.4 Key Developments 104
10.13.5 SWOT Analysis 104
10.13.6 Key Strategies 104
10.14 Regulus Therapeutics, Inc. 105
10.14.1 Company Overview 105
10.14.2 Financial Overview 105
10.14.3 Products/Services Offered 105
10.14.4 Key Developments 105
10.14.5 SWOT Analysis 106
10.14.6 Key Strategies 106
10.15 Siemens Healthineers 107
10.15.1 Company Overview 107
10.15.2 Financial Overview 107
10.15.3 Products/Services Offered 108
10.15.4 Key Developments 108
10.15.5 SWOT Analysis 108
10.15.6 Key Strategies 108
10.16 Shenzhen New Industries Biomedical Engineering Co., Ltd 109
10.16.1 Company Overview 109
10.16.2 Financial Overview 109
10.16.3 Products/Services Offered 109
10.16.4 Key Developments 109
10.16.5 SWOT Analysis 109
10.16.6 Key Strategies 109
10.17 Xeptagen SpA 110
10.17.1 Company Overview 110
10.17.2 Financial Overview 110
10.17.3 Products/Services Offered 110
10.17.4 Key Developments 110
10.17.5 SWOT Analysis 110
10.17.6 Key Strategies 110
11 Appendix
11.1 References 111
11.2 Related Reports 111
12 List Of Tables
TABLE 1 NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET: PIPELINE ANALYSIS 28
TABLE 2 NAFLD ASSOCIATED DISEASE CONDITIONS 30
TABLE 3 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 33
TABLE 4 GLOBAL NASH BIOMARKERS MARKET FOR SERUM BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 34
TABLE 5 CLASSIFICATION OF LIVER FIBROSIS BIOMARKERS 35
TABLE 6 GLOBAL NASH BIOMARKERS MARKET FOR HEPATIC FIBROSIS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 36
TABLE 7 GLOBAL NASH BIOMARKERS MARKET FOR APOPTOSIS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 37
TABLE 8 GLOBAL NASH BIOMARKERS MARKET FOR OXIDATIVE STRESS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 38
TABLE 9 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 40
TABLE 10 GLOBAL NASH BIOMARKERS MARKET FOR PHARMACEUTICAL COMPANIES AND CRO, BY REGION, 2020–2027 (USD MILLION) 41
TABLE 11 GLOBAL NASH BIOMARKERS MARKET FOR RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY REGION,
2020–2027 (USD MILLION) 42
TABLE 12 GLOBAL NASH BIOMARKERS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 43
TABLE 13 GLOBAL NASH BIOMARKERS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 44
TABLE 14 GLOBAL NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 46
TABLE 15 AMERICAS: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 48
TABLE 16 AMERICAS: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 48
TABLE 17 AMERICAS: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 49
TABLE 18 NORTH AMERICA: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 50
TABLE 19 NORTH AMERICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 50
TABLE 20 NORTH AMERICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 51
TABLE 21 US: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 51
TABLE 22 US: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 52
TABLE 23 CANADA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 52
TABLE 24 CANADA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 53
TABLE 25 LATIN AMERICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53
TABLE 26 LATIN AMERICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 54
TABLE 27 EUROPE: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 56
TABLE 28 EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56
TABLE 29 EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 57
TABLE 30 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 58
TABLE 31 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59
TABLE 32 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 59
TABLE 33 UK: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 60
TABLE 34 UK: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 60
TABLE 35 GERMANY: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61
TABLE 36 GERMANY: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 61
TABLE 37 FRANCE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62
TABLE 38 FRANCE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 62
TABLE 39 ITALY: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 63
TABLE 40 ITALY: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 63
TABLE 41 SPAIN: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 64
TABLE 42 SPAIN: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 64
TABLE 43 REST OF WESTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65
TABLE 44 REST OF WESTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 65
TABLE 45 EASTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 66
TABLE 46 EASTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 66
TABLE 47 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 68
TABLE 48 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68
TABLE 49 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 69
TABLE 50 JAPAN: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69
TABLE 51 JAPAN: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 70
TABLE 52 CHINA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70
TABLE 53 CHINA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 71
TABLE 54 INDIA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 71
TABLE 55 INDIA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 72
TABLE 56 AUSTRALIA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72
TABLE 57 AUSTRALIA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 73
TABLE 58 SOUTH KOREA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73
TABLE 59 SOUTH KOREA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 74
TABLE 60 REST OF ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 61 REST OF ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 75
TABLE 62 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 63 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 64 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 78
TABLE 65 MIDDLE EAST: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 66 MIDDLE EAST: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 79
TABLE 67 AFRICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79
TABLE 68 AFRICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 80
TABLE 69 TOP MANUFACTURERS IN THE GLOBAL NASH BIOMARKERS MARKET 81
13 List Of Figures
FIGURE 1 MARKET SYNOPSIS 15
FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL NASH BIOMARKERS MARKET 16
FIGURE 3 GLOBAL NASH BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) 16
FIGURE 4 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 17
FIGURE 5 GLOBAL NASH BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) 17
FIGURE 6 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 17
FIGURE 7 GLOBAL NASH BIOMARKERS MARKET: MARKET STRUCTURE 18
FIGURE 8 RESEARCH PROCESS OF MRFR 19
FIGURE 9 TOP-DOWN & BOTTOM-UP APPROACH 22
FIGURE 10 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 23
FIGURE 11 VALUE CHAIN: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 26
FIGURE 12 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 27
FIGURE 13 GLOBAL NASH BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) 32
FIGURE 14 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 33
FIGURE 15 GLOBAL NASH BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) 39
FIGURE 16 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 40
FIGURE 17 GLOBAL NASH BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) 45
FIGURE 18 GLOBAL NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 46
FIGURE 19 AMERICAS: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 47
FIGURE 20 NORTH AMERICA: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 49
FIGURE 21 EUROPE: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 55
FIGURE 22 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 58
FIGURE 23 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 67
FIGURE 24 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 76
FIGURE 25 GLOBAL NASH BIOMARKERS MARKET: COMPETITIVE LANDSCAPE 82
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.
